JPH07196526A - Inhibitor of collagenase - Google Patents
Inhibitor of collagenaseInfo
- Publication number
- JPH07196526A JPH07196526A JP6001039A JP103994A JPH07196526A JP H07196526 A JPH07196526 A JP H07196526A JP 6001039 A JP6001039 A JP 6001039A JP 103994 A JP103994 A JP 103994A JP H07196526 A JPH07196526 A JP H07196526A
- Authority
- JP
- Japan
- Prior art keywords
- leaf
- collagenase
- leaves
- plant
- flower
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明はコラゲナーゼ阻害剤に関
し、更に詳細にはコラーゲンの分解酵素であるコラゲナ
ーゼの活性を阻害するコラゲナーゼ阻害成分が含有され
ているコラゲナーゼ阻害剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a collagenase inhibitor, and more particularly to a collagenase inhibitor containing a collagenase inhibitor which inhibits the activity of collagenase, which is a degrading enzyme of collagen.
【０００２】[0002]
【従来の技術】人間の皮膚や関節を取り巻く筋肉は、コ
ラーゲンなるタンパク質とエラスチンなるタンパク質と
の編目構造によって、その形状等が保持されている。こ
のため、紫外線の照射や自己消化によってコラーゲンが
分解され、コラーゲン繊維を再生するに充分なコラーゲ
ンが補充されなかったとき、皮膚の弛みやシワの原因と
なる。また、リューマチ性関節炎は、免疫代謝異常によ
る自己消化によって、関節のコラーゲン繊維が分解され
るために起こるとされている。ところで、コラーゲンの
消失は、体内に存在するコラーゲンの分解酵素であるコ
ラゲナーゼによってもなされる。従って、選択的に皮膚
真皮や目的部位にて、コラゲナーゼの活性を阻害するこ
とができれば、皮膚の弛みやシミの進行、或いはリュー
マチ症状の進行の遅延を期待できる。かかる観点からコ
ラゲナーゼの阻害剤について、化粧品素材や医薬品材料
として研究されている。2. Description of the Related Art The shape of the muscle surrounding human skin and joints is maintained by the stitch structure of a protein called collagen and a protein called elastin. For this reason, collagen is decomposed by irradiation of ultraviolet rays and self-digestion, and when insufficient collagen is replenished to regenerate collagen fibers, it causes looseness and wrinkles of the skin. Rheumatoid arthritis is said to occur because collagen fibers in joints are decomposed by autolysis due to abnormal immune metabolism. By the way, the disappearance of collagen is also caused by collagenase which is a collagen degrading enzyme existing in the body. Therefore, if it is possible to selectively inhibit the activity of collagenase in the dermis of the skin or the target site, it is expected that the slackening of the skin, the progression of spots, or the progression of rheumatic symptoms is delayed. From this viewpoint, inhibitors of collagenase have been studied as cosmetic materials and pharmaceutical materials.
【０００３】[0003]
【発明が解決しようとする課題】この様に、コラゲナー
ゼ阻害剤が配合された化粧品等によれば、コラゲーンの
不足に因る皮膚の弛み等を防止し、皮膚の張り等の維持
を期待し得る。しかしながら、現在研究されている殆ど
のコラゲナーゼ阻害剤が合成品であるため、敏感な皮膚
に直接付着する化粧品等に合成品のコラゲナーゼ阻害剤
を配合することには問題がある。そこで、本発明の目的
は、敏感な皮膚に直接付着し得る天然物から得られ、コ
ラゲナーゼ阻害成分を含有するコラゲナーゼ阻害剤を提
供することにある。As described above, according to the cosmetics or the like containing the collagenase inhibitor, it is possible to prevent the loosening of the skin due to lack of collagen and to maintain the skin tension. . However, since most of the collagenase inhibitors currently studied are synthetic products, there is a problem in incorporating the synthetic collagenase inhibitor into cosmetics or the like that directly adhere to sensitive skin. Therefore, an object of the present invention is to provide a collagenase inhibitor obtained from a natural product that can be directly attached to sensitive skin and containing a collagenase inhibitor.
【０００４】[0004]
【課題を解決するための手段】本発明者は、前記目的を
達成すべく種々の植物を使用して抽出した抽出物のコラ
ゲナーゼ阻害率を調査した結果、ザクロ実、レモンバー
ム葉等の特定の植物を凍結乾燥し粉砕した植物粉砕物を
水抽出して得られた水抽出物は、コラゲナーゼ阻害率が
高いことを見出し、本発明に到達した。Means for Solving the Problems As a result of investigating the collagenase inhibition rate of extracts extracted using various plants in order to achieve the above-mentioned object, the present inventors have found that specific plants such as pomegranate seeds, lemon balm leaves, etc. The present inventors have found that the water extract obtained by water-extracting the pulverized plant pulverized product obtained by freeze-drying and pulverizing it has a high collagenase inhibitory rate, and thus arrived at the present invention.
【０００５】即ち、本発明は、ザクロ実、レモンバーム
実及び葉、ゲンノショウコ葉、キンミズヒキ葉、オレガ
ノ葉、ウツボグサ葉、トラノヲ花及び葉、アブラチャン
実、ノイバラ花、サルトリイバラ花、クリ葉、マツヨイ
草花、及びワレモコウ葉から成る植物群から選ばれた少
なくとも一種の原料植物から得られた植物乾燥粉末であ
って、該植物乾燥粉末を水抽出して得られた抽出液中
に、コラーゲンの分解酵素であるコラゲナーゼの活性を
阻害するコラゲナーゼ阻害成分が含有されていることを
特徴とするコラゲナーゼ阻害剤にある。かかる構成を有
する本発明において、植物乾燥粉末１００ｇから水又は
温水２００リットルによって抽出して得られた水抽出液
のコラゲナーゼ阻害率が１０％以上であるとき、コラゲ
ナーゼ阻害能を有する入浴剤として、当該植物乾燥粉末
を使用することができる。また、植物乾燥粉末が、原料
植物を凍結乾燥した後に粉砕して得られた植物乾燥粉末
であることによって、乾燥途中のコラゲナーゼ阻害成分
の損失を可及的に少なくできる。That is, the present invention is directed to pomegranate seeds, lemon balm fruits and leaves, ginkgo biloba leaves, Quercus japonicus leaves, oregano leaves, Nepenthes leaves, Tranowo flowers and leaves, Abrachan seeds, Neubarra flowers, Sartoli rose flowers, chestnut leaves, matsuyoi flowers, And a plant dry powder obtained from at least one raw material plant selected from the group of plants consisting of oleander leaves, in the extract obtained by water-extracting the plant dry powder, a collagen degrading enzyme. The collagenase inhibitor is characterized in that it contains a collagenase inhibitor that inhibits the activity of collagenase. In the present invention having such a constitution, when the collagenase inhibitory rate of the water extract obtained by extracting from 100 g of the plant dry powder with 200 liters of water or warm water is 10% or more, as a bath agent having a collagenase inhibiting ability, Plant dry powder can be used. Further, since the dry plant powder is a dry plant powder obtained by freeze-drying a raw material plant and then pulverizing it, the loss of the collagenase inhibitory component during the drying process can be minimized.
【０００６】[0006]
【作用】本発明によれば、コラゲナーゼ阻害率の高い抽
出液を得ることができ、しかもかかる抽出液中に含有さ
れているコラゲナーゼ阻害成分は、天然物である植物か
ら抽出されたものであって、合成品ではない。このた
め、本発明によって得られた抽出液は、直接皮膚に付け
ることができ、化粧品や入浴剤として使用できる。According to the present invention, an extract having a high collagenase inhibitory rate can be obtained, and the collagenase-inhibiting component contained in the extract is a natural product extracted from a plant. , Not a synthetic product. Therefore, the extract obtained by the present invention can be directly applied to the skin and can be used as a cosmetic or a bath agent.
【０００７】[0007]
【発明の概要】本発明では、ザクロ実、レモンバーム実
及び葉、ゲンノショウコ葉、キンミズヒキ葉、オレガノ
葉、ウツボグサ葉、トラノヲ花及び葉、アブラチャン
実、ノイバラ花、サルトリイバラ花、クリ葉、マツヨイ
草花、及びワレモコウ葉から成る植物群から選ばれた少
なくとも一種を原料として使用することが大切である。
前記植物群において、ザクロ実、レモンバーム葉、ゲン
ノショウコ葉、キンミズヒキ葉、アブラチャン実、オレ
ガノ葉、及びウツボグサ葉から成る植物群から得られば
れた少なくとも一種を原料として使用することが、コラ
ゲナーゼ阻害成分を充分に含有する抽出液を得ることが
でき好ましい。就中、ザクロ実及び／又はレモンバーム
葉を原料として使用することが、入浴剤等に使用した場
合、香り及び使用量等の観点から好ましい。一方、前記
植物群以外の植物を原料として使用した場合、コラゲナ
ーゼ阻害成分を充分に含有する抽出液を得るためには、
大量の原料植物を必要とする。SUMMARY OF THE INVENTION In the present invention, pomegranate seeds, lemon balm seeds and leaves, ginkgo leaves, Quercus japonicus leaves, oregano leaves, Nepenthes leaves, Tranowo flowers and leaves, Abrachan seeds, Neubara flowers, Sartoli rose flowers, chestnut leaves, matsuyoi flowers, It is important to use, as a raw material, at least one selected from the group of plants consisting of and leaves of oleander.
In the group of plants, pomegranate seeds, lemon balm leaves, ginkgo biloba leaves, Quercus japonicus leaves, Abrachan seeds, oregano leaves, and using at least one obtained from a group of plants consisting of Nepenthes leaves, a collagenase inhibitory component. It is preferable since an extract containing a sufficient amount can be obtained. Above all, it is preferable to use pomegranate seeds and / or lemon balm leaves as a raw material from the viewpoint of fragrance and usage amount when used as a bathing agent or the like. On the other hand, when a plant other than the plant group is used as a raw material, in order to obtain an extract containing sufficient collagenase inhibitory components,
Requires a large amount of raw plants.
【０００８】また、本発明では、原料植物を乾燥して得
られた植物乾燥粉末を、水又は温水によって抽出する。
この乾燥操作としては、凍結乾燥を採用することが好ま
しい。乾燥途中において、原料植物中に存在するコラゲ
ナーゼ阻害成分の損失を可及的に少なくできるためであ
る。ここで、原料植物を乾燥することなく水又は温水抽
出しても、コラゲナーゼ阻害成分の抽出は可能である。
しかし、抽出液中のコラゲナーゼ阻害成分を所定量以上
とするには、大量の原料植物を必要とし、抽出作業を煩
雑なものとする。尚、本発明において言う「温水抽出」
とは、温度が３５〜４５℃程度の温水を使用して行う抽
出をいう。Further, in the present invention, the plant dry powder obtained by drying the raw material plant is extracted with water or warm water.
Freeze-drying is preferably adopted as the drying operation. This is because the loss of the collagenase inhibitory component present in the raw material plant can be minimized during the drying process. Here, the collagenase inhibitory component can be extracted by extracting the raw material plant with water or hot water without drying.
However, a large amount of raw material plants is required to make the collagenase inhibitory component in the extract more than a predetermined amount, which makes the extraction work complicated. The "hot water extraction" referred to in the present invention
The term "extraction" refers to extraction using warm water having a temperature of about 35 to 45 ° C.
【０００９】本発明においては、植物乾燥粉末１００ｇ
から水又は温水２００リットルによって抽出して得られ
た水抽出液のコラゲナーゼ阻害率が１０％以上であるこ
とが、植物乾燥粉末を入浴剤として好適に使用できる。
また、植物乾燥粉末を水抽出して得られた抽出液を、必
要に応じて固液分離した分離液を濃縮した濃縮液又は固
形物にしてもよい。この濃縮液又は固形物を入浴剤とし
て使用する場合には、必要に応じて水や温水に再溶解し
て使用することができる。かかる濃縮液又は固形物は、
２〜２０ｇ、好ましくは５ｇを、水又は温水２００リッ
トル中に添加した際に、２００リットルの水又は温水に
おけるコラゲナーゼ阻害率が１０％以上となるように、
コラゲナーゼ阻害成分の濃縮度を調整することが好まし
い。In the present invention, 100 g of plant dry powder
It is preferable that the plant dry powder is used as a bathing agent when the collagenase inhibitory rate of the water extract obtained by extracting with 200 liters of water or 200 liters of warm water is 10% or more.
Further, the extract obtained by extracting the plant dry powder with water may be made into a concentrated liquid or a solid matter in which the separated liquid obtained by solid-liquid separation is concentrated, if necessary. When this concentrated liquid or solid is used as a bathing agent, it can be redissolved in water or warm water as needed and used. Such concentrated liquid or solid matter,
When 2 to 20 g, preferably 5 g, is added to 200 liters of water or warm water, the collagenase inhibition rate in 200 liters of water or warm water is 10% or more,
It is preferable to adjust the concentration of the collagenase inhibiting component.
【００１０】以上、述べてきた本発明において言う「コ
ラゲナーゼ阻害率」は、下記の方法で測定したものであ
る。本発明でのコラゲナーゼ阻害率は、Wunsch等のコラ
ゲナーゼ阻害活性試験方法[E.Wunsch et al.,Hoppe-Sey
er's Z.Physiol Chem.,333,149〜151(1963)]に基づいて
測定した。つまり、合成基質(4-Phenylazobenzyloxycar
bonyl-Pro-Leu-Gly-Pro- D Arg)を、Clostridium histo
lyticum由来のコラエナーゼによって分解し、合成基質
の分解率を測定した。この測定は、本発明において得ら
れた植物乾燥粉末から水抽出された抽出液に合成基質を
加えた被試験溶液に、コラエナーゼを加え、３７℃で１
５分間保持した後、コラエナーゼを酸性化失活させた。
次いで、コラエナーゼの作用で生じた分解物(4-Phenyla
zobenzyloxycarbonyl-Pro-Leu)を酢酸エチルによって抽
出し、抽出液の３２０ｎｍにおける吸光度（Ａ１）を測
定した。更に、合成基質に蒸留水のみを加えた合成基質
溶液についても、Ａ１の測定と同様にして吸光度（Ｂ
１）を測定した。The "collagenase inhibition rate" referred to in the present invention described above is measured by the following method. The collagenase inhibitory rate in the present invention is determined by the collagenase inhibitory activity test method of Wunsch et al. [E. Wunsch et al., Hoppe-Sey].
er's Z. Physiol Chem., 333, 149-151 (1963)]. In other words, a synthetic substrate (4-Phenylazobenzyloxycar
bonyl-Pro-Leu-Gly-Pro- D Arg), Clostridium histo
It was degraded by collagenase derived from lyticum and the degradation rate of the synthetic substrate was measured. This measurement was carried out by adding collagenase to a test solution prepared by adding a synthetic substrate to an extract obtained by extracting water from the plant dry powder obtained in the present invention, and adding 1 at 37 ° C.
After holding for 5 minutes, the collagenase was acidified and inactivated.
Next, the degradation product (4-Phenyla
zobenzyloxycarbonyl-Pro-Leu) was extracted with ethyl acetate, and the absorbance (A1) of the extract at 320 nm was measured. Furthermore, for the synthetic substrate solution prepared by adding only distilled water to the synthetic substrate, the absorbance (B
1) was measured.
【００１１】また、被試験溶液に酸性化失活させたコラ
エナーゼを加えた他は、Ａ１と同様にして吸光度（Ａ
２）を測定すると共に、合成基質溶液についても、Ａ２
と同様にして吸光度（Ｂ２）を測定した。測定した吸光
度（Ａ１、Ａ２、Ｂ１、Ｂ２）を用い、下記式によって
コラゲナーゼ阻害率（Ｃ）を算出した。 Ｃ（％）＝〔（Ｂ１−Ｂ２）−（Ａ１−Ａ２）〕／（Ａ
１−Ａ２）×１００ 上記式において、コラエナーゼの活性が阻害されない場
合には、コラゲナーゼ阻害率（Ｃ）は０％となり、コラ
エナーゼの活性が完全に阻害された場合には、コラゲナ
ーゼ阻害率（Ｃ）は１００％となる。The absorbance (A) was measured in the same manner as A1 except that the acid-inactivated collagenase was added to the test solution.
In addition to measuring 2), A2
The absorbance (B2) was measured in the same manner as. Using the measured absorbance (A1, A2, B1, B2), the collagenase inhibition rate (C) was calculated by the following formula. C (%) = [(B1-B2)-(A1-A2)] / (A
1-A2) × 100 In the above formula, when the activity of collagenase is not inhibited, the collagenase inhibition rate (C) is 0%, and when the activity of collagenase is completely inhibited, the collagenase inhibition rate (C). Is 100%.
【００１２】[0012]
実施例１ 採取した種々の植物片を冷凍した後、２４時間の真空乾
燥を施し、水分含有率０．１％未満の乾燥物とした。そ
の後、この乾燥物を１ｍｍ画以下の粉末に粉砕してから
冷凍保存した。次いで、冷凍保存した粉末の０．５ｇを
採取し、蒸留水４０ｃｃを加えて１５分間の攪拌抽出
（２０００ｒｐｍ、２５℃）を行った。更に、攪拌抽出
が終了した後、遠心分離機によって遠心分離（１２００
０ｒｐｍ、１５分間）を行い、上澄液を被測定原液とし
た。また、被測定原液を５倍に希釈した５倍希釈液、１
０倍に希釈した１０倍希釈液も、被測定液とした。この
様にして得られた被測定原液、５倍希釈液、及び１０倍
希釈液の各々について、上述した測定方法によってコラ
ゲナーゼ阻害率（Ｃ）を測定し、下記表１に示した。Example 1 Various collected plant pieces were frozen and then vacuum dried for 24 hours to obtain a dried product having a water content of less than 0.1%. Then, the dried product was crushed into powder having a size of 1 mm or less and then stored frozen. Next, 0.5 g of the powder that had been frozen and stored was collected, 40 cc of distilled water was added, and stirring extraction (2000 rpm, 25 ° C.) was performed for 15 minutes. Furthermore, after the stirring extraction is completed, a centrifugal separator (1200
(0 rpm, 15 minutes), and the supernatant was used as the stock solution to be measured. In addition, a 5-fold diluted solution in which the stock solution to be measured is diluted 5-fold, 1
A 10-fold diluted solution diluted 0-fold was also used as the solution to be measured. The collagenase inhibitory rate (C) was measured by the above-mentioned measuring method for each of the stock solutions to be measured, the 5-fold diluted solution, and the 10-fold diluted solution thus obtained, and the results are shown in Table 1 below.
【００１３】 表１ サンプル名 コラゲナーゼ阻害率（Ｃ）〔単位：％〕 被測定原液 ５倍希釈液 １０倍希釈液 ザクロ 実 １００ ７６ ３９ レモンバーム 葉 ８０ ５５ ３８ ゲンノショウコ葉 １００ ９５ ３２ キンミズヒキ 葉 ９６ ７４ ２４ アブラチャン 実 １００ ４９ ２４ ノイバラ 花 ９７ ５０ ２３ オレガノ 葉 ９１ ５３ １０ ウツボグザ 葉 １００ ８２ １０ トラノヲ 花葉 １００ ５９ ９ クリ 葉 ９４ ５２ ８ マツヨイ草 花 ９１ ５４ ７ ワレモコウ 葉 ８６ ５４ ７ サルトリイバラ花 １００ ５８ ６ レモンバーム 実 １００ ５１ ６ ハッカ 葉 ６３ ５８ −３ タイム 葉 ７６ ５８ −１１Table 1 Sample name Collagenase inhibition rate (C) [unit:%] Undiluted solution to be measured 5 times diluted solution 10 times diluted solution Pomegranate seed 100 76 39 Lemon balm leaf 80 55 55 38 Genoshoko leaf 100 95 32 Quercus cypress leaf 96 74 24 24 Abra Chan Fruit 100 49 24 Neurose Flower 97 50 50 23 Oregano Leaf 91 53 10 Utsubogza Leaf 100 100 82 10 Tranowo Flower Leaf 100 59 9 9 Kuri Leaf 94 52 52 8 Matsuyoi Flower 91 91 54 7 Waremoko Leaf 86 86 54 7 100 Bari Fruit Tree 51 6 mint leaf 63 58 -3 thyme leaf 76 58-11
【００１４】表１から明らかな様に、ザクロ実、レモン
バーム実及び葉、ゲンノショウコ葉、キンミズヒキ葉、
オレガノ葉、ウツボグサ葉、トラノヲ花及び葉、アブラ
チャン実、ノイバラ花、サルトリイバラ花、クリ葉、マ
ツヨイ草花、又はワレモコウ葉、特にザクロ実、レモン
バーム葉、ゲンノショウコ葉、キンミズヒキ葉、オレガ
ノ葉、アブラチャン実、又はウツボグサ葉を原料植物と
して使用して得られた抽出液においては、被測定原液、
５倍希釈液、及び１０倍希釈液において良好なコラゲナ
ーゼ阻害率を示した。As is clear from Table 1, pomegranate seeds, lemon balm seeds and leaves, ginkgo biloba leaves, buttercup leaves,
Oregano leaves, Nepenthes leaves, Tranowo flowers and leaves, Abrachan seeds, Neubara flowers, Sartoli rose flowers, chestnut leaves, matsuyoi flowers, or Valerian leaves, especially pomegranate seeds, lemon balm leaves, Genus ginger leaves, Quercus cypress leaves, oregano leaves, Abrachan seeds , Or in the extract obtained by using the plant of Nepenthes as a raw material plant, the undiluted solution to be measured,
The 5-fold diluted solution and the 10-fold diluted solution showed a good collagenase inhibition rate.
【００１５】実施例２ 実施例１において得られた植物粉末を温水２００リット
ルに添加・抽出して得られた抽出液中のコラゲナーゼ阻
害率を測定し、コラゲナーゼ阻害率が１０％以上とする
に必要な植物粉末量を測定した。その結果を下記の表２
に示す。 表２ サンプル名 必要な粉末量（ｇ） ザクロ 実 １９ レモンバーム 葉 １４ ゲンノショウコ葉 ２２ キンミズヒキ 葉 ４４ アブラチャン 実 ４８ ノイバラ 花 ６７ オレガノ 葉 １０１ ウツボグザ 葉 １０３ トラノヲ 花葉 ７４ クリ 葉 ９６ マツヨイ草 花 １０７ ワレモコウ 葉 １０１ サルトリイバラ花 １１４ レモンバーム 実 １０９ かかる植物粉末を入浴剤として使用する場合、植物粉末
の添加量を５０ｇ以下とすることが好ましく、ザクロ
実、レモンバーム葉、ゲンノショウコ葉、キンミズヒキ
葉、又はアブラチャン葉が好ましい。特に、ザクロ実又
はレモンバーム葉が香り等の点からも好適である。Example 2 The plant powder obtained in Example 1 was added to 200 liters of warm water and extracted, and the collagenase inhibitory rate in the extract obtained was measured to be required for the collagenase inhibitory rate to be 10% or more. The amount of various plant powders was measured. The results are shown in Table 2 below.
Shown in. Table 2 Sample name Required amount of powder (g) Pomegranate seed 19 Lemon balm leaf 14 Gensho ginger leaf 22 Kinmizuhiki leaf 44 Abrachan seed 48 Neurose flower 67 Oregano leaf 101 Utsubogusa leaf 103 Toranowo flower leaf 74 Chestnut leaf 96 Pinegrass sprouts leaf 107 Saltoli rose flower 114 Lemon balm fruit 109 When such a plant powder is used as a bathing agent, the amount of the plant powder added is preferably 50 g or less, and pomegranate fruit, lemon balm leaf, Genus ginseng leaf, Quercus cypress leaf, or Abrachan leaf is preferable. In particular, pomegranate seeds or lemon balm leaves are preferable from the viewpoint of fragrance and the like.
【００１６】実施例３ 実施例１において得られた植物粉末１００ｇを水１リッ
トルにて１５分間の攪拌抽出（２００ｒｐｍ、２５℃）
した後、遠心分離機を使用して遠心分離（６０００ｒｐ
ｍ、３０分間）して上澄液を得た。この上澄液を温水２
００リットルに添加してコラゲナーゼ阻害率を測定し、
コラゲナーゼ阻害率が１０％以上とするに必要な上澄液
量を測定した。その結果を下記の表３に示す。 表３ サンプル名 必要な上澄液量（ｃｃ） ザクロ 実 ２００ レモンバーム 葉 １５０ ゲンノショウコ葉 ２５０ キンミズヒキ 葉 ５００ アブラチャン 実 ５００ ノイバラ 花 ７００ オレガノ 葉 １０００ ウツボグザ 葉 １０００ トラノヲ 花葉 ７５０ クリ 葉 １０００ マツヨイ草 花 １０００ ワレモコウ 葉 １０００ サルトリイバラ花 １０００ レモンバーム 実 １０００Example 3 100 g of the plant powder obtained in Example 1 was extracted with 1 liter of water under stirring for 15 minutes (200 rpm, 25 ° C.).
After that, centrifuge using a centrifuge (6000 rp
m, 30 minutes) to obtain a supernatant. This supernatant is warmed with 2
Add to 00 liters to measure collagenase inhibition rate,
The amount of supernatant liquid required for the collagenase inhibition rate to be 10% or more was measured. The results are shown in Table 3 below. Table 3 Sample name Required amount of supernatant liquid (cc) Pomegranate seed 200 Lemon balm leaf 150 Gennoshoko leaf 250 Quercus japonicus leaf 500 Abrachan seed 500 Neubara flower 700 Oregano leaf 1000 Utsuboguza leaf 1000 Toranowo flower leaf 750 Chestnut leaf 1000 flower Leaf 1000 Sartoli Rose Flower 1000 Lemon Balm Fruit 1000
【００１７】実施例４ 実施例１において得られたレモンバーム葉の粉末１００
ｇを水１リットルにて１５分間の攪拌抽出（２００ｒｐ
ｍ、２５℃）した後、遠心分離機を使用して遠心分離
（６０００ｒｐｍ、３０分間）して上澄液を得た。次い
で、この上澄液を凍結乾燥して１０ｇの固形物とした。
得られた固形物の１．５ｇを温水２００リットルに溶解
すると、温水のコラゲナーゼ阻害率を１０％することが
できた。Example 4 Lemon balm leaf powder 100 obtained in Example 1
g with 1 liter of water for 15 minutes with stirring (200 rp
m, 25 ° C.), followed by centrifugation (6000 rpm, 30 minutes) using a centrifuge to obtain a supernatant. Then, this supernatant was freeze-dried to obtain 10 g of a solid.
When 1.5 g of the obtained solid matter was dissolved in 200 liters of warm water, the collagenase inhibition rate of warm water could be 10%.
【００１８】[0018]
【発明の効果】本発明のコラゲナーゼ阻害剤中のコラゲ
ナーゼ阻害成分は、天然物であるため、皮膚に直接付け
ることができる。このため、本発明のコラゲナーゼ阻害
剤を入浴剤等として使用することによって、皮膚真皮や
目的部位にて、コラゲナーゼの活性を阻害し、皮膚の弛
みやシミの進行、或いはリューマチ症状の進行の遅延を
期待できる。INDUSTRIAL APPLICABILITY Since the collagenase-inhibiting component in the collagenase inhibitor of the present invention is a natural product, it can be directly applied to the skin. Therefore, by using the collagenase inhibitor of the present invention as a bath agent or the like, at the skin dermis and the target site, inhibit the activity of collagenase, the progression of skin slackness and stains, or the delay of the progression of rheumatism symptoms. Can be expected.
【手続補正書】[Procedure amendment]
【提出日】平成７年３月２９日[Submission date] March 29, 1995
【手続補正１】[Procedure Amendment 1]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】０００２[Name of item to be corrected] 0002
【補正方法】変更[Correction method] Change
【補正内容】[Correction content]
【０００２】[0002]
【従来の技術】人間の皮膚や関節を取り巻く筋肉は、コ
ラーゲンなるタンパク質とエラスチンなるタンパク質と
の編目構造によって、その形状等が保持されている。か
かるコラーゲンは、紫外線の照射や自己消化によって分
解されるものであって、リューマチ性関節炎は、免疫代
謝異常による自己消化によって、関節のコラーゲン繊維
が分解されるために起こるとされている。ところで、コ
ラーゲンの消失は、体内に存在するコラーゲンの分解酵
素であるコラゲナーゼによってもなされる。従って、選
択的に皮膚真皮や目的部位にて、コラゲナーゼの活性を
阻害することができれば、リューマチ症状の進行の遅延
を期待できる。かかる観点からコラゲナーゼの阻害剤に
ついて、化粧品素材や医薬品材料として研究されてい
る。2. Description of the Related Art The shape of the muscle surrounding human skin and joints is maintained by the stitch structure of a protein called collagen and a protein called elastin. Or
Light collagen is separated by UV irradiation and self-digestion.
Be those that are solutions, re Yumachi arthritis, by autolysis by the immune metabolism, joints of collagen fibers is to occur in order to be decomposed. By the way, the disappearance of collagen is also caused by collagenase which is a collagen degrading enzyme existing in the body. Thus, in selectively skin dermis or the target site, if it is possible to inhibit the activity of collagenase, it can be expected delay of progression of Li Yumachi symptoms. From this viewpoint, inhibitors of collagenase have been studied as cosmetic materials and pharmaceutical materials.
【手続補正２】[Procedure Amendment 2]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】０００３[Name of item to be corrected] 0003
【補正方法】変更[Correction method] Change
【補正内容】[Correction content]
【０００３】[0003]
【発明が解決しようとする課題】この様に、コラゲナー
ゼ阻害剤が配合された化粧品等によれば、コラゲーンの
不足によって発生する種々の問題の解決、例えばリュー
マチ症状の進行の遅延を可能とすることが期待し得る。
しかしながら、現在研究されている殆どのコラゲナーゼ
阻害剤が合成品であるため、敏感な皮膚に直接付着する
化粧品等に合成品のコラゲナーゼ阻害剤を配合すること
には問題がある。そこで、本発明の目的は、敏感な皮膚
に直接付着し得る天然物から得られ、コラゲナーゼ阻害
成分を含有するコラゲナーゼ阻害剤を提供することにあ
る。[Problems that the Invention is to Solve Thus, according to the cosmetics of collagenase inhibitor is blended, solve various problems thus occur a lack of Koragen, eg Liu
It can be expected to allow the progression of gusset symptoms to be delayed .
However, since most of the collagenase inhibitors currently studied are synthetic products, there is a problem in incorporating the synthetic collagenase inhibitor into cosmetics or the like that directly adhere to sensitive skin. Therefore, an object of the present invention is to provide a collagenase inhibitor obtained from a natural product that can be directly attached to sensitive skin and containing a collagenase inhibitor.
【手続補正３】[Procedure 3]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】００１８[Correction target item name] 0018
【補正方法】変更[Correction method] Change
【補正内容】[Correction content]
【００１８】[0018]
【発明の効果】本発明のコラゲナーゼ阻害剤中のコラゲ
ナーゼ阻害成分は、天然物であるため、皮膚に直接付け
ることができる。このため、本発明のコラゲナーゼ阻害
剤を入浴剤等として使用することによって、皮膚真皮や
目的部位にて、コラゲナーゼの活性を阻害し、コラーゲ
ンの不足に因り発生する種々の問題の解決、例えばリュ
ーマチ症状の進行の遅延を期待できる。INDUSTRIAL APPLICABILITY Since the collagenase-inhibiting component in the collagenase inhibitor of the present invention is a natural product, it can be directly applied to the skin. Therefore, by using the collagenase inhibitor of the present invention as a bath agent or the like, the collagenase activity is inhibited in the skin dermis and the target site, and collagenase is produced.
It can be expected to solve various problems caused by the lack of drug , for example , delay the progression of rheumatic symptoms.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ａ６１Ｋ 7/50 ─────────────────────────────────────────────────── ───Continued from the front page (51) Int.Cl. 6 Identification code Internal reference number FI technical display area A61K 7/50
Claims (3)
ノショウコ葉、キンミズヒキ葉、オレガノ葉、ウツボグ
サ葉、トラノヲ花及び葉、アブラチャン実、ノイバラ
花、サルトリイバラ花、クリ葉、マツヨイ草花、及びワ
レモコウ葉から成る植物群から選ばれた少なくとも一種
の原料植物から得られた植物乾燥粉末であって、 該植物乾燥粉末を水抽出して得られた抽出液中に、コラ
ーゲンの分解酵素であるコラゲナーゼの活性を阻害する
コラゲナーゼ阻害成分が含有されていることを特徴とす
るコラゲナーゼ阻害剤。1. From pomegranate seeds, lemon balm fruits and leaves, ginkgo biloba leaves, butterbur leaves, oregano leaves, nepenthes leaves, tranowo flowers and leaves, abrachan berries, noibara flowers, sartoli rose flowers, chestnut leaves, matsuyoi grass flowers, and vaginalis leaves. A plant dry powder obtained from at least one raw material plant selected from the group consisting of plants, wherein the extract obtained by water-extracting the plant dry powder contains the activity of collagenase, which is a collagen-degrading enzyme. A collagenase inhibitor comprising a collagenase inhibitor that inhibits.
００リットルによって抽出して得られた水抽出液のコラ
ゲナーゼ阻害率が１０％以上である請求項１記載のコラ
ゲナーゼ阻害剤。2. Water or hot water 2 from 100 g of plant dry powder
The collagenase inhibitor according to claim 1, wherein the water extract obtained by extraction with 00 liter has a collagenase inhibitory rate of 10% or more.
た後に粉砕して得られた植物乾燥粉末である請求項１記
載のコラゲナーゼ阻害剤。3. The collagenase inhibitor according to claim 1, wherein the dry plant powder is a dry plant powder obtained by lyophilizing a raw material plant and then pulverizing it.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6001039A JPH07196526A (en) | 1994-01-11 | 1994-01-11 | Inhibitor of collagenase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6001039A JPH07196526A (en) | 1994-01-11 | 1994-01-11 | Inhibitor of collagenase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH07196526A true JPH07196526A (en) | 1995-08-01 |
Family
ID=11490427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6001039A Pending JPH07196526A (en) | 1994-01-11 | 1994-01-11 | Inhibitor of collagenase |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH07196526A (en) |
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09165313A (en) * | 1995-12-15 | 1997-06-24 | Kao Corp | Skin preparation for external use |
| JPH10291929A (en) * | 1997-04-21 | 1998-11-04 | Nagase & Co Ltd | Wrinkle suppressive preparation for external use for skin |
| WO1998052588A1 (en) * | 1997-05-21 | 1998-11-26 | Medion Research Laboratories Inc. | Therapeutic agents for respiratory diseases |
| JPH1179970A (en) * | 1997-09-03 | 1999-03-23 | Shiseido Co Ltd | Collagenase inhibitor |
| JP2000256122A (en) * | 1999-03-03 | 2000-09-19 | Shiseido Co Ltd | Matrix metalloproteinases inhibitor |
| JP2002097149A (en) * | 2000-09-20 | 2002-04-02 | Noevir Co Ltd | Skin care preparation |
| JP2002104952A (en) * | 2000-09-28 | 2002-04-10 | Noevir Co Ltd | Skin case preparation |
| FR2817747A1 (en) * | 2000-12-11 | 2002-06-14 | Oreal | USE OF AT LEAST ONE SAPOGENIN, OR A NATURAL EXTRACT CONTAINING SAME, TO PREVENT THE SIGNS OF SKIN AGING |
| JP2002356406A (en) * | 2001-05-29 | 2002-12-13 | Noevir Co Ltd | Skin care preparation |
| KR20030025067A (en) * | 2001-09-19 | 2003-03-28 | 정창호 | Composition of cosmetics contains punica extracts |
| EP1349558A1 (en) * | 2000-12-12 | 2003-10-08 | Angiolab, Inc. | Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| KR100431393B1 (en) * | 2001-08-16 | 2004-05-14 | 주식회사 태평양 | Cosmetic Composition for the Inhibition of Sebum Secretion Containing the Extracts of the Fruits of Prunus Mume and Punica Granatum |
| KR100473688B1 (en) * | 2001-02-20 | 2005-03-07 | 주식회사 안지오랩 | Pharmaceutical composition containing melissa extract for the use of matrix metalloproteinase inhibitor |
| JP2005200334A (en) * | 2004-01-15 | 2005-07-28 | Ichimaru Pharcos Co Ltd | Method for preventing or ameliorating skin aging or skin disease |
| JP2007522161A (en) * | 2004-02-13 | 2007-08-09 | コグニス・フランス・ソシエテ・パール・アクシオン・サンプリフィエ | Cosmetic composition containing castanea sativa leaf extract |
| KR100794517B1 (en) * | 2006-06-29 | 2008-01-16 | (주)더페이스샵코리아 | A cosmetic composition for wrinkle improvement containing a extract of Prunella vulgaris |
| CN100386066C (en) * | 2006-02-22 | 2008-05-07 | 黎秋萍 | Production process of fresh flower-algae bath agent |
| KR100853120B1 (en) * | 2007-04-02 | 2008-08-21 | (주)더페이스샵코리아 | Cosmetic composions containing prunella vulgaris extracts stablized in nanoliposome |
| JP2009040757A (en) * | 2007-08-10 | 2009-02-26 | Maruzen Pharmaceut Co Ltd | Agent promoting laminin 5 production, agent normalizing dermal basement membrane, and agent promoting recovery of skin lesion |
| KR100903654B1 (en) * | 2007-10-10 | 2009-06-18 | (주)더페이스샵코리아 | Cosmetic compositions comprising Prunella Vulgaris extract and Adenosine |
| US7897184B1 (en) | 2009-08-13 | 2011-03-01 | Access Business Group International Llc | Topical composition with skin lightening effect |
| US8034385B2 (en) | 2002-07-08 | 2011-10-11 | Coty B.V. | Anti-ageing skin cosmetic |
| JP2012116766A (en) * | 2010-11-29 | 2012-06-21 | Kao Corp | Cgrp responsiveness suppressor |
| JP2013245170A (en) * | 2012-05-23 | 2013-12-09 | Nippon Menaade Keshohin Kk | Hyaluronic acid synthesis promoter and skin care preparation |
| JP2014521698A (en) * | 2011-08-05 | 2014-08-28 | ステムテック インターナショナル， インコーポレイテッド | Skin care composition containing a combination of natural ingredients |
| US9155773B2 (en) | 2001-12-12 | 2015-10-13 | Angiolab, Inc. | Antiobesity composition |
-
1994
- 1994-01-11 JP JP6001039A patent/JPH07196526A/en active Pending
Cited By (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09165313A (en) * | 1995-12-15 | 1997-06-24 | Kao Corp | Skin preparation for external use |
| JPH10291929A (en) * | 1997-04-21 | 1998-11-04 | Nagase & Co Ltd | Wrinkle suppressive preparation for external use for skin |
| WO1998052588A1 (en) * | 1997-05-21 | 1998-11-26 | Medion Research Laboratories Inc. | Therapeutic agents for respiratory diseases |
| US6309674B1 (en) | 1997-05-21 | 2001-10-30 | Medion Research Laboratories | Therapeutic agents for respiratory diseases |
| JPH1179970A (en) * | 1997-09-03 | 1999-03-23 | Shiseido Co Ltd | Collagenase inhibitor |
| JP2000256122A (en) * | 1999-03-03 | 2000-09-19 | Shiseido Co Ltd | Matrix metalloproteinases inhibitor |
| JP2002097149A (en) * | 2000-09-20 | 2002-04-02 | Noevir Co Ltd | Skin care preparation |
| JP2002104952A (en) * | 2000-09-28 | 2002-04-10 | Noevir Co Ltd | Skin case preparation |
| FR2817747A1 (en) * | 2000-12-11 | 2002-06-14 | Oreal | USE OF AT LEAST ONE SAPOGENIN, OR A NATURAL EXTRACT CONTAINING SAME, TO PREVENT THE SIGNS OF SKIN AGING |
| WO2002047650A1 (en) * | 2000-12-11 | 2002-06-20 | L'oreal | Use of at least a sapogenin for preventing skin ageing symptoms |
| EP1349558A1 (en) * | 2000-12-12 | 2003-10-08 | Angiolab, Inc. | Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| EP1349558A4 (en) * | 2000-12-12 | 2004-03-24 | Angiolab Inc | Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| US7485327B2 (en) * | 2000-12-12 | 2009-02-03 | Angiolab, Inc. | Composition comprising Melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| KR100473688B1 (en) * | 2001-02-20 | 2005-03-07 | 주식회사 안지오랩 | Pharmaceutical composition containing melissa extract for the use of matrix metalloproteinase inhibitor |
| JP2002356406A (en) * | 2001-05-29 | 2002-12-13 | Noevir Co Ltd | Skin care preparation |
| KR100431393B1 (en) * | 2001-08-16 | 2004-05-14 | 주식회사 태평양 | Cosmetic Composition for the Inhibition of Sebum Secretion Containing the Extracts of the Fruits of Prunus Mume and Punica Granatum |
| KR20030025067A (en) * | 2001-09-19 | 2003-03-28 | 정창호 | Composition of cosmetics contains punica extracts |
| US9155773B2 (en) | 2001-12-12 | 2015-10-13 | Angiolab, Inc. | Antiobesity composition |
| US8034385B2 (en) | 2002-07-08 | 2011-10-11 | Coty B.V. | Anti-ageing skin cosmetic |
| JP2005200334A (en) * | 2004-01-15 | 2005-07-28 | Ichimaru Pharcos Co Ltd | Method for preventing or ameliorating skin aging or skin disease |
| US8067044B2 (en) | 2004-02-13 | 2011-11-29 | Cognis France S.A.S. | Cosmetic compositions containing an extract of leaves of the Castanea sativa plant and cosmetic treatments |
| JP2007522161A (en) * | 2004-02-13 | 2007-08-09 | コグニス・フランス・ソシエテ・パール・アクシオン・サンプリフィエ | Cosmetic composition containing castanea sativa leaf extract |
| CN100386066C (en) * | 2006-02-22 | 2008-05-07 | 黎秋萍 | Production process of fresh flower-algae bath agent |
| KR100794517B1 (en) * | 2006-06-29 | 2008-01-16 | (주)더페이스샵코리아 | A cosmetic composition for wrinkle improvement containing a extract of Prunella vulgaris |
| KR100853120B1 (en) * | 2007-04-02 | 2008-08-21 | (주)더페이스샵코리아 | Cosmetic composions containing prunella vulgaris extracts stablized in nanoliposome |
| JP2009040757A (en) * | 2007-08-10 | 2009-02-26 | Maruzen Pharmaceut Co Ltd | Agent promoting laminin 5 production, agent normalizing dermal basement membrane, and agent promoting recovery of skin lesion |
| KR100903654B1 (en) * | 2007-10-10 | 2009-06-18 | (주)더페이스샵코리아 | Cosmetic compositions comprising Prunella Vulgaris extract and Adenosine |
| US7897184B1 (en) | 2009-08-13 | 2011-03-01 | Access Business Group International Llc | Topical composition with skin lightening effect |
| US8202556B2 (en) | 2009-08-13 | 2012-06-19 | Access Business Group International Llc | Topical composition with skin lightening effect |
| JP2012116766A (en) * | 2010-11-29 | 2012-06-21 | Kao Corp | Cgrp responsiveness suppressor |
| JP2014521698A (en) * | 2011-08-05 | 2014-08-28 | ステムテック インターナショナル， インコーポレイテッド | Skin care composition containing a combination of natural ingredients |
| JP2013245170A (en) * | 2012-05-23 | 2013-12-09 | Nippon Menaade Keshohin Kk | Hyaluronic acid synthesis promoter and skin care preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH07196526A (en) | Inhibitor of collagenase | |
| Pedrosa et al. | Anti-wrinkle and anti-whitening effects of jucá (Libidibia ferrea Mart.) extracts | |
| JP6054700B2 (en) | Desugaring agent and external preparation for skin | |
| CN110731991A (en) | Skin external composition with acne removing effect | |
| KR101704874B1 (en) | Cosmetic Compositions with Whitening and Anti-oxidative Effect Comprising of Phragmitis Rhizoma, Salicomia herbacea L. and Prunus mume | |
| JP2005255527A (en) | Composition for in vivo collagen synthesis promotor | |
| JP2003212770A (en) | Maillard reaction inhibitor | |
| JP2001220312A (en) | Cosmetic composition containing steam distillate of plant | |
| JPH09110710A (en) | Dermal preparation for external use and bathing agent | |
| JP2001213750A (en) | Cosmetic composition containing steam-distilled water of rosaceae plant | |
| JP2003012531A (en) | Collagenease activity inhibitor or cosmetic composition | |
| JP2001226219A (en) | Cosmetic composition containing plant steam distillation water | |
| KR20160091166A (en) | natural cosmetic composition for removing callus and improving skin barrier function | |
| Chaudhary et al. | A comparative study of the antioxidant and ACE inhibitory activities of selected herbal extracts | |
| Jahan et al. | Cardioprotective Potential of Gemmomodified Extract of Terminalia arjuna against Chemically Induced Myocardial Injury in Rabbits. | |
| JP2003206225A (en) | Cosmetic composition and beauty and healt food composition | |
| Ajisafe et al. | Snail mucus from Achatina fulica as a biomaterial exhibits pro-survival effects on human chondrocytes | |
| Wahid et al. | Phytochemical Profiling and Antioxidant Activities of Red Ginger (Zingiber officinale var. rubrum) Cultivated Eco-Farming. | |
| JP2016138148A (en) | External preparation for skin | |
| JP2003073287A (en) | Hyaluronidase activity inhibitor or cosmetic composition | |
| Senthilkumar et al. | Remineralisation potential of grape seed, ginger honey-an in vitro study | |
| Hwang et al. | Antioxidant activities and nitric oxide production of medicine plants in Gyeongsangbukdo (Carthamus tinctorius seed, Cyperus rotundus, Schizonepeta tenuifolia, Polygonatum odoratum var. pluriflorum, Paeonia lactiflora) | |
| Yimam et al. | A Standardized Composition Comprised of Extracts from Rosmarinus officinalis, Annona squamosa and Zanthoxylum clava-herculis for Cellulite | |
| Hemmati et al. | Wound healing effects of persian Oak (Quercus brantii) ointment in rats | |
| Hebi et al. | Leaf aqueous extract of Argania spiniosa exhibits antihyperglycemic effect in diabetic rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050830 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051014 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051206 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060404 |